Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Net Margin for 6 consecutive years, with 12.91% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 2142.0% year-over-year to 12.91%, compared with a TTM value of 0.19% through Dec 2025, up 2719.0%, and an annual FY2025 reading of 0.19%, up 2719.0% over the prior year.
  • Net Margin was 12.91% for Q4 2025 at Xeris Biopharma Holdings, up from 0.83% in the prior quarter.
  • Across five years, Net Margin topped out at 12.91% in Q4 2025 and bottomed at 308.95% in Q2 2021.
  • Average Net Margin over 5 years is 82.48%, with a median of 42.86% recorded in 2022.
  • The sharpest move saw Net Margin crashed -6418bps in 2021, then soared 20548bps in 2022.
  • Year by year, Net Margin stood at 234.16% in 2021, then soared by 83bps to 39.01% in 2022, then increased by 23bps to 30.16% in 2023, then soared by 72bps to 8.51% in 2024, then soared by 252bps to 12.91% in 2025.
  • Business Quant data shows Net Margin for XERS at 12.91% in Q4 2025, 0.83% in Q3 2025, and 2.7% in Q2 2025.